ProBioGen, a service and technology provider for complex therapeutic glycoproteins, and Chiome Bioscience, a Japanese antibody discovery and development company, have signed a service and license agreement under which ProBioGen will apply its enhanced cancer cell-killing technology GlymaxX to Chiome’s LIV-1205, an antibody clinical candidate program.

ProBioGen will develop a stable GlymaxX cell line, followed by process development and GMP manufacturing of the ADCC-enhanced cancer stem cell antibody, which will be optimized for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) cancer cell-killing activity.
Dr. Koji Nakamura, head of drug discovery labs and former chief executive officer of LivTech said,
 
“We have tested ProBioGen’s GlymaxX technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, made our selection quite simple.”
 
ProBioGen’s chief executive officer Wieland Wolf, said, “We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers.”